Atiye ÇENGEL, Koray DEMİREL, Mehmet KİTAPÇI, Mustafa CEMRİ, Numan EKİM, İ. Kıvılcım OĞUZÜLGEN

Submasif pulmoner tromboembolide trombolitik tedavinin sonuçları

Masif pulmoner tromboembolide (PTE) trombolitik tedavi ile mortalite ve morbiditenin azaldığı kabul edilmektedir. Bu çalışmanın amacı da ekokardiyografık (EKO) bulgularla submasif PTE tanısı konan hastalarda verilen rt-PA tedavisinin erken ve geç dönemde sağ kalp fonksiyonlarına ve akciğer reperfüzyonuna olan etkisini değerlendirmektir. Semptom, bulgu, ventilasyon-perfüzyon sintigrafisi ve EKO kardiyograflk bulgularla submasif PTE tanısı alan yaş ortalaması 57.5, ortalama semptom süresi 5.6 gün olan 6 hastaya tanı anında 100 mg rt-PA 2 saatlik infüzyonla uygulandı. Infüzyon sonrası heparin ve oral antikoagülanla tedavileri 3 aya tamamlanan hastalar, tedavinin 24-36. saatinde, 10. gününde ve 3. ayında tekrar değerlendirildiler. Başlangıç ortalama diyastol sonu sağ ventrikül çapı 47 ± 2.9 mm, sağ atrium çapı 48.5 ± 5.6 mm, maksimum sistolik pulmoner arter basıncı 66.6 ±11.6 mmHg olan hastaların ortalama kalp hızı 111 ± 19/dakika, kan basıncı 105/70 mmHg idi. Tedavinin 24-36. saatinde bu değerler sırasıyla; 40.5 ± 5.9 mm, 40 ± 4.3 mm, 39.1±16.2 mmHg, 94 ± 5.5/dakika, 116/76 mmHg oldu (p< 0.05). Düzelme 10. günde de devam ederken (p< 0.05), 3. ay kontrolünde kalp fonksiyonlarının ve hemodinaminin tama yakın düzeldiği izlendi (sırasıyla; 31.6 ± 4.9 mm, 31 ± 5.7 mm, 28 ± 11.5 mmHg, p

The results of thrombolytic therapy in submassive pulmonary thromboembolism

Thrombolysis appers to be lifesaving in patients with massive pulmonary embolism (PE). The aim of this study was to determine the acute and long term effects of thrombolytic therapy (rt-PA) on right ventricle dimension, systolic pulmonary ar-tery pressure, hemodynamic parameters and the reperfusion of the lung in submassive PE. Six patients (mean age 57.5 ± 12.1, mean symptom time 5.6 ± 3.6 days) were accepted as submassive PE on the bases of clinical suspicion, high-probability ventilation-perfusion lung scan and echocardiographic findings. They all had 100 mg rt-PA/2 hours followed by heparin and warfarin for 3 months. They were evaluated at 24-36 hours of therapy, at day 10 and at the end of anticoagulan therapy. The initial mean end diastolic dimension of right ventricul was 47 + 2.9 mm, dimension of right atrium was 48.5 ± 5.6 mm, maximum systolic pulmonary artery pressure 66.6 + 11.6 mmHg, hearth rate 111 + 19/min, arterial pressure 105/70 mmHg. All these parameters improved significantly at 24-36 hr of rt-PA (40.5 ±5.9 mm, 40 ± 4.3 mm, 39.1 ±16.2 mmHg, 94 ± 5.5/min, 116/76 mmHg respectively, p< 0.05). The improvement was better in day 10. All patients had nearly normal cardiac functions (31.6 ± 4.9 mm, 31 ± 5.7 mm, 28 ± 11.5 mmHg, respectively, p< 0.05) in the 3rd months' of their ECHO control. When the perfusion scans were scored by the degree of pulmonary vasculary obstruction, the initial score was 65.16%. On the 10th day the score decreased to 30.79% (p< 0.05), at the end of 3 months the mean score was 16%. As a result with the use of thrombolytic therapy, cardiac recovery and reperfusion of lung begin early and improvement continues to normal findings at the end of 3 months.

PDF

___

1. Tapson VF, Witty LA. Massive pulmonary embolism, diagnostic and therapeutic strategies. Clin Chest Ned 1995; 16: 329-40.
2. Goldhaber ZS. Contemporary pulmonary embolism thrombolysis. Int J Cardiol 1998; 65 (Suppl 1): 91-3.
3. Ekim N. Trombolitik tedavi. Metintaş M (editör). Pulmoner Tromboemboli. Eskişehir: ASD Toraks Yayınları, 2001: 173-81.
4. The PIOPED Invastigators. Value of uentilation/perfusion scan in acute pulmonary embolism. JAMA 1990; 263: 2753-9.
5. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and loui-molecutar-weight heparin: Mechanisms of action, phar-macokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (Suppl): 489-510.
6. Meyer G, Collignon MA, Guinet F, et al, Comparison of perfusion lung scanning and angiography in the estimation of vascular obstruction in acute pulmonary embolism. Eur J Nuc Med 1990; 17:315-9.
7. Oğuzülgen IK, Ekim N, Cemri M ue ark. Pulmoner tromboemboli tedavisinde standart heparin İle düşük molekül ağırlıklı heparin tedavisinin etkinliğinin karşılaştırılması. Toraks Dergisi 2001; 2: 31-4.
8. Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998; 339:93-104.
9. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: A comprehensive review of current evidence. Chest 1999; 115: 1695-707.
10. Dalen JE, Banas JS, Brooks HL, et al. Resolution rate of acute pulmonary embolism in man. N Engl J Med 1969; 280: 1194-9.
11. Prediletto R, Paoletti P, Fornai E. Natural course of treated pulmonary embolism: Evaluation by perfusion lung scintigraphy, gas exchange, and chest roentgenogram. Chest 1990;97:554-61.
12. Cannon CP, Goldhaber SZ. Cardiovascular risk stratification of pulmonary embolism. Am J Cardiol 1995; 78: 1149-51.
13. Hyers TM. Venous thromboembolism. Am J Respir Crit Care Med 1999; 159: 1-14.
14. Goldhaber SZ. Contemporary pulmonary embolism thrombolysis. Chest 1995; 107:45-51.
15. The Urokinase Pulmonary Embolism Trial. JAMA 1970; 214:2163-72.
16. Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism, N Engl J Med 1980; 303: 842-5.
17. Jerjes-Sanchez C, Ramirez-Rivera A, Garcia M de L, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis 1995; 2: 227-9.
18. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: Randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341:507-11.
19. Grifoni S, Oliuotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2001; 101:2817-22.
20. Konstantinides S, Geibel A, Olschewski M, et at. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry. Circulation 1997; 96: 882-8.
21. Ribeiro A, Lindmaker P, Juhlin-Dannfelt A, et al. Echocardiography Doppler in pulmonary embolism: Right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997; 134: 479-87.
22. Goldhaber SZ. Pulmonary embolism thrombolysis: Do we need another agent? Am Heart J 1999; 138: 1-2.
23. Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase us alteplase in massive pulmonary embolism. Eur Heart J 1997; 18: 1141-8.
24. Pacouret G, Barnes SJ, Hopkins G, Bernard C. Rapid Haemodynamic Improvement following saruplase in recent massive pulmonary embolism. Thromb Haemost 1998; 79: 264-7.
25. Task Force Report: Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000,
26. Goldhaber SZ Thrombolytic therapy in venous thromboembolism. Clinical trials and current indications. Clin Chest Med 1995; 16: 307-20.